Miramel (Pramipexole Dihydrochloride Monohydrate)

Pramipexole Dihydrochloride Monohydrate, the active ingredient in Miramel, is a dopamine agonist presented as a tablet for oral use. It is marketed in the European Union and is indicated for the management of Parkinson's disease and restless legs syndrome in adult patients. The drug works by stimulating dopamine receptors to improve motor control.

GNH USA supplies Miramel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Miramel (pramipexole) is used in disorders that involve dopaminergic deficiency or dysfunction.

- Parkinson's disease: improves motor symptoms such as tremor, rigidity and bradykinesia. - Restless legs syndrome: reduces the urge to move the legs and associated discomfort. - Parkinson's disease – early motor fluctuations: helps control wearing‑off phenomena and delayed onset dyskinesia.

Pramipexole may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: sensation of light‑headedness, especially on standing. - Somnolence: increased sleepiness or fatigue. - Edema: swelling of the lower extremities.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances that may require discontinuation. - Impulse control disorders: compulsive gambling, shopping or hypersexuality. - Orthostatic hypotension: marked drop in blood pressure upon standing leading to fainting.

When prescribing Miramel, clinicians should consider several safety measures.

- Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Cardiovascular disease: monitor for hypotension and arrhythmias, especially in elderly patients. - Psychiatric history: observe for emergence of hallucinations or impulse control disorders. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Pramipexole can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol, risperidone): may antagonize dopamine agonist effect. - MAO‑B inhibitors (e.g., selegiline, rasagiline): combined use can increase risk of hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., quinidine): may raise pramipexole plasma levels.

Moderate Interactions (Monitor Closely): - Opioids (e.g., morphine, oxycodone): additive central nervous system depression. - Alcohol: enhances sedation and dizziness. - Antihypertensive agents: may potentiate orthostatic hypotension. - SSRIs or SNRIs: monitor for increased risk of impulse control behaviors.